ClinicalTrials.gg
CompletedNCT05161715Updated Jan 29, 2025Results posted

Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease

A Phase 2 interventional study of Obicetrapib in Early Alzheimer's Disease, sponsored by NewAmsterdam Pharma. Completed at 1 site in Netherlands. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-29.

Sponsored by NewAmsterdam Pharma · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 134 studies in Alzheimer Disease with a site in Netherlands — 17 open to participants now, 28 under way, 10 of them phase 3. Alzheimer Disease · Netherlands.

Enrollment
117th of 120
13 · median 246
Started
2022
with 11 others
Phase 2
31 of 134
1 open now
Registered
94th of 134
by date

Among the 134 studies in Alzheimer Disease with a site in Netherlands, this one is the 117th largest by enrollment of the 120 interventional ones that give a count, is one of 12 that started in 2022, is one of 31 in phase 2, and was the 94th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

17 of the 134 studies in Alzheimer Disease with a site in Netherlands are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 134 studies in Alzheimer Disease with a site in Netherlands, or all of them as a file.
02

Study summary

A Phase 2a study in men and women with early Alzheimer's disease to evaluate the pharmacodynamics, pharmacokinetics and safety of obicetrapib therapy.

Read the detailed description

This study will be a proof of concept, Phase 2a study in patients with early Alzheimer's disease (clinical diagnosis of Alzheimer's disease Stage 3 or 4 based on the National Institute on Aging Alzheimer's Association Research Framework criteria) to evaluate the Pharmacodynamic, cognitive effects, Pharmacokinetic, and safety and tolerability of obicetrapib therapy.

03

Conditions studied

  • Early Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • men \& women 50-75 years
  • or women not of
  • diagnosis of Alzheimer's disease based on National Institute for Aging:
  • Biomarker classification A+T+N+ or A+T+N-
  • Clinical Stage 3 or 4 with Clinical Dementia Rating score >/= 0.5 \& \</= 1; (MMSE) score >/=20
  • Have an APOE genotype of E4/E4 or E3/E4
  • not on or on stabilized AD medication
  • Patient \& study partner willing to sign consent

Exclusion criteria

Exclusion Criteria:

  • Other than AD, disorder that may impair cognition
  • for MRI
  • History of neurological, psychiatric or mental conditions;

    • history stroke
    • MI
    • Type 1 diabetes \& Type 2 with >8%
    • BP > 150/90 mmHg
    • renal or hepatic impaired
    • hyperaldosteronism
    • cancer
    • depression
    • laboratory abnormalities
    • not able to undergo lumbar puncture
    • taking certain medications including lipid altering
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    10mg obicetrapib tablets

    10mg obicetrapib (5mg tablets) administered orally daily for 24 weeks

    Drug: Obicetrapib

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Percent Change in Apolipoprotein A-I (ApoA-I) in Cerebrospinal Fluid (CSF)

    Mean percent change from screening (V1) to end of treatment (V6) in ApoA-I in CSF

    Time frame: 24 weeks

  2. Mean Percent Change in Apolipoprotein A-I (ApoA-I) in Plasma

    Mean percent change in ApoA-I in plasma from baseline (V2) to week 24 (V6)

    Time frame: 24 weeks

  3. Mean Percent Change in Apolipoprotein-E (ApoE) in Cerebrospinal Fluid (CSF)

    Mean percent change from screening (V1) to end of treatment (V6) in ApoE

    Time frame: 24 weeks

  4. Mean Percent Change in Apolipoprotein-E (ApoE) in Plasma

    Mean percent change from baseline (V2) to week 24 (V6) in plasma in ApoE

    Time frame: 24 weeks

  5. Small HDL (s-HDL) Particle Concentration in Cerebrospinal Fluid (CSF) at Baseline

    Small high-density lipoprotein (s-HDL) particle concentration in cerebrospinal fluid (CSF) measured by Ion Mobility Assay (https://doi.org/10.1002/alz.12649)

    Time frame: baseline

  6. Small HDL (s-HDL) Particle Concentration in Cerebrospinal Fluid (CSF) at Week 24

    Small high-density lipoprotein (s-HDL) particle concentration in CSF measured by Ion Mobility Assay (https://doi.org/10.1002/alz.12649)

    Time frame: Week 24

  7. Small HDL (s-HDL) Particle Concentration in Plasma at Baseline

    Small high-density lipoprotein (s-HDL) particle concentration plasma measured by Ion Mobility Assay. For more information on the measurement used please refer to this article: https://doi.org/10.1002/alz.12649

    Time frame: baseline

  8. Small HDL (s-HDL) Particle Concentration in Plasma at Week 24

    Small high-density lipoprotein (s-HDL) particle concentration in plasma measured by Ion Mobility Assay at Week 24 For more information on the measurement used please refer to this article: https://doi.org/10.1002/alz.12649

    Time frame: Week 24

  9. Mean Percent Change in Cholesterol Efflux Capacity in Cerebrospinal Fluid (CSF)

    Mean percent change in cholesterol efflux capacity in CSF from screening (V1) to week 24 (V6)

    Time frame: 24 weeks

07

Results

Posted Nov 19, 2024

Participant flow

Participant flow — Overall Study
Milestone10mg Obicetrapib
Started13
Completed13
Not completed0

Outcome measures

PrimaryMean Percent Change in Apolipoprotein A-I (ApoA-I) in Cerebrospinal Fluid (CSF)

Mean percent change from screening (V1) to end of treatment (V6) in ApoA-I in CSF

Time frame:
24 weeks
Reported as:
Mean · percent change from screening visit
Mean Percent Change in Apolipoprotein A-I (ApoA-I) in Cerebrospinal Fluid (CSF)
percent change from screening visit10mg Obicetrapib
Mean Percent Change in Apolipoprotein A-I (ApoA-I) in Cerebrospinal Fluid (CSF)-8.4 ± 13.6
Statistical analysis
  • 10mg Obicetrapib · Wilcoxon (Mann-Whitney) · p = 0.425 (No multiple testing correction was performed)
PrimaryMean Percent Change in Apolipoprotein A-I (ApoA-I) in Plasma

Mean percent change in ApoA-I in plasma from baseline (V2) to week 24 (V6)

Time frame:
24 weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in Apolipoprotein A-I (ApoA-I) in Plasma
percent change from baseline10mg Obicetrapib Tablets
Mean Percent Change in Apolipoprotein A-I (ApoA-I) in Plasma37.5 ± 25.2
Statistical analysis
  • 10mg Obicetrapib Tablets · Wilcoxon (Mann-Whitney) · p = 0.0002 (No multiple testing correction was performed)
PrimaryMean Percent Change in Apolipoprotein-E (ApoE) in Cerebrospinal Fluid (CSF)

Mean percent change from screening (V1) to end of treatment (V6) in ApoE

Time frame:
24 weeks
Reported as:
Mean · percent change from screening
Mean Percent Change in Apolipoprotein-E (ApoE) in Cerebrospinal Fluid (CSF)
percent change from screening10mg Obicetrapib Tablets
Mean Percent Change in Apolipoprotein-E (ApoE) in Cerebrospinal Fluid (CSF)3.9 ± 10.3
Statistical analysis
  • 10mg Obicetrapib Tablets · Wilcoxon (Mann-Whitney) · p = 0.0424 (No multiple testing correction was performed)
PrimaryMean Percent Change in Apolipoprotein-E (ApoE) in Plasma

Mean percent change from baseline (V2) to week 24 (V6) in plasma in ApoE

Time frame:
24 weeks
Reported as:
Mean · percent change from baseline
Mean Percent Change in Apolipoprotein-E (ApoE) in Plasma
percent change from baseline10mg Obicetrapib Tablets
Mean Percent Change in Apolipoprotein-E (ApoE) in Plasma47.8 ± 46.9
Statistical analysis
  • 10mg Obicetrapib Tablets · Wilcoxon (Mann-Whitney) · p = 0.001 (No multiple testing correction was performed)
PrimarySmall HDL (s-HDL) Particle Concentration in Cerebrospinal Fluid (CSF) at Baseline

Small high-density lipoprotein (s-HDL) particle concentration in cerebrospinal fluid (CSF) measured by Ion Mobility Assay (https://doi.org/10.1002/alz.12649)

Time frame:
baseline
Reported as:
Mean · average relative abundance
Small HDL (s-HDL) Particle Concentration in Cerebrospinal Fluid (CSF) at Baseline
average relative abundance10mg Obicetrapib Tablets
Small HDL (s-HDL) Particle Concentration in Cerebrospinal Fluid (CSF) at Baseline0.542 ± 0.138
PrimarySmall HDL (s-HDL) Particle Concentration in Cerebrospinal Fluid (CSF) at Week 24

Small high-density lipoprotein (s-HDL) particle concentration in CSF measured by Ion Mobility Assay (https://doi.org/10.1002/alz.12649)

Time frame:
Week 24
Reported as:
Mean · average relative abundance
Small HDL (s-HDL) Particle Concentration in Cerebrospinal Fluid (CSF) at Week 24
average relative abundance10mg Obicetrapib Tablets
Small HDL (s-HDL) Particle Concentration in Cerebrospinal Fluid (CSF) at Week 240.542 ± 0.106
PrimarySmall HDL (s-HDL) Particle Concentration in Plasma at Baseline

Small high-density lipoprotein (s-HDL) particle concentration plasma measured by Ion Mobility Assay. For more information on the measurement used please refer to this article: https://doi.org/10.1002/alz.12649

Time frame:
baseline

No measurements were reported for this outcome.

PrimarySmall HDL (s-HDL) Particle Concentration in Plasma at Week 24

Small high-density lipoprotein (s-HDL) particle concentration in plasma measured by Ion Mobility Assay at Week 24 For more information on the measurement used please refer to this article: https://doi.org/10.1002/alz.12649

Time frame:
Week 24

No measurements were reported for this outcome.

PrimaryMean Percent Change in Cholesterol Efflux Capacity in Cerebrospinal Fluid (CSF)

Mean percent change in cholesterol efflux capacity in CSF from screening (V1) to week 24 (V6)

Time frame:
24 weeks
Reported as:
Mean · percent change from screening
Mean Percent Change in Cholesterol Efflux Capacity in Cerebrospinal Fluid (CSF)
percent change from screening10mg Obicetrapib Tablets
Mean Percent Change in Cholesterol Efflux Capacity in Cerebrospinal Fluid (CSF)1.9 ± 24.1
Statistical analysis
  • 10mg Obicetrapib Tablets · Wilcoxon (Mann-Whitney) · p = 0.556 (No multiple testing correction was performed)

Adverse events

Collected over From first dose of study drug through Week 24.5. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
10mg Obicetrapib Tablets0/13 (0%)0/13 (0%)9/13 (69.2%)
Most frequent other events
Showing 10 of 26
Most frequent other events
Event10mg Obicetrapib Tablets
HeadacheNervous system disorders2/13
Normocytic anemiaBlood and lymphatic system disorders1/13
Angina pectorisCardiac disorders1/13
Benign paroxysmal positional vertigoEar and labyrinth disorders1/13
ConstipationGastrointestinal disorders1/13
Loose stoolsGastrointestinal disorders1/13
ObstipationGastrointestinal disorders1/13
Reflux esophagitisGastrointestinal disorders1/13
Unilateral leg swellingGeneral disorders1/13
Covid-19Infections and infestations1/13

Baseline characteristics

Baseline Population is defined as all participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)10mg Obicetrapib
Mean64.5 ± 6.2
Sex: Female, Male
Sex: Female, Male(Participants)10mg Obicetrapib
Female12
Male1
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)10mg Obicetrapib
08

Study locations

1 site
  • Brain Research Center Amsterdam
    Amsterdam, Netherlands
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in May 2023, 15 months.

Results were first posted in Nov 2024, 1 year 6 months after primary completion.

Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 15 months is below that.

Counting every sponsor, half of 258 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2021
First posted
Dec 17, 2021
StartActual
Jan 12, 2022
Primary completionActual
May 9, 2023
CompletionActual
Jun 1, 2023
Results first posted
Nov 19, 2024
Last update
Jan 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05161715
Lead sponsor
NewAmsterdam Pharma
Responsible party
Sponsor
First posted
Dec 17, 2021
Start date
Jan 12, 2022
Primary completion
May 9, 2023
Completion
Jun 1, 2023
Results posted
Nov 19, 2024
Last update
Jan 29, 2025

Study contacts

Marc Ditmarsch, MD
study director · NewAmsterdam Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TA-8995

Start the discussion